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ABSTRACT
Background
Somatic afferent input to the spinal cord from a peripheral inflammatory site can modulate
the peripheral response. However, the intracellular signaling mechanisms in the spinal cord
that regulate this linkage have not been defined. Previous studies suggest spinal cord p38
mitogen-activated protein (MAP) kinase and cytokines participate in nociceptive behavior. We
therefore determined whether these pathways also regulate peripheral inflammation in rat
adjuvant arthritis, which is a model of rheumatoid arthritis.
Methods and Findings
Selective blockade of spinal cord p38 MAP kinase by administering the p38 inhibitor
SB203580 via intrathecal (IT) catheters in rats with adjuvant arthritis markedly suppressed paw
swelling, inhibited synovial inflammation, and decreased radiographic evidence of joint
destruction. The same dose of SB203580 delivered systemically had no effect, indicating that
the effect was mediated by local concentrations in the neural compartment. Evaluation of
articular gene expression by quantitative real-time PCR showed that spinal p38 inhibition
markedly decreased synovial interleukin-1 and  6 and matrix metalloproteinase (MMP3) gene
expression. Activation of p38 required tumor necrosis factor a (TNFa) in the nervous system
because IT etanercept (a TNF inhibitor) given during adjuvant arthritis blocked spinal p38
phosphorylation and reduced clinical signs of adjuvant arthritis.
Conclusions
These data suggest that peripheral inflammation is sensed by the central nervous system
(CNS), which subsequently activates stress-induced kinases in the spinal cord via a TNFa-
dependent mechanism. Intracellular p38 MAP kinase signaling processes this information and
profoundly modulates somatic inflammatory responses. Characterization of this mechanism
could have clinical and basic research implications by supporting development of new
treatments for arthritis and clarifying how the CNS regulates peripheral immune responses.
The Editors’ Summary of this article follows the references.
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Central nervous system (CNS) regulation of peripheral
inﬂammation may be a component of many immunological
diseases, including rheumatoid arthritis. However, the mech-
anisms that allow the CNS to modulate peripheral inﬂam-
matory responses are largely unknown. For instance, neural
mechanisms were recently described in which activation of
glutamate receptors in the spinal cord dorsal horn alters skin
and joint inﬂammation [1–3]. The spinal mechanisms,
particularly the intracellular signaling pathways that inte-
grate somatic afferent input and modulate peripheral
inﬂammatory responses, have not been elucidated.
Recent data demonstrate that mitogen-activated protein
(MAP) kinases, p38 in particular, can be activated in the
spinal cord by peripheral noxious stimuli [4]. We considered
that p38 might participate in reﬂexes that modulate
peripheral inﬂammation. To test this hypothesis, expression
and function of spinal p38 were evaluated in a model of
chronic inﬂammation. We then tested whether TNFa serves
as a key intermediary by activating spinal p38 in the same
model. These pathways could potentially deﬁne a novel
paradigm in which peripheral tissue inﬂammation is sensed
by the CNS, most likely through somatic afferent pathways,
resulting in p38 MAP kinase activation in spinal cord and
subsequent modulation of peripheral responses.
Methods
Intrathecal Catheterization of Rats
Isoﬂurane-anesthetized Lewis rats (200–250 g) were im-
planted with an intrathecal (IT) catheter modiﬁed from the
methodpreviouslydescribed[5].Aftera6drecoveryperiod,all
animals except those that appeared to have sensory or motor
abnormalities (fewer than 5% of the total number) were used
for experiments. For IT administration, 10 ll of drug or saline
followed by 10 ll of isotonic saline was injected through the
catheter. All animals were handled in accordance with USDA
guidelines, and all procedures have been carefully reviewed
and approved by the institutional animal subjects committee.
Adjuvant Arthritis and Drug Treatment
Lewis rats were immunized at the base of the tail with 0.1
ml of complete Freund’s adjuvant (CFA) on day 0 several days
after catheter implantation (n¼6/group). Drug (p38 inhibitor
SB203580 or vehicle) treatment was generally started on day 8
and continued daily until day 20. For etanercept experiments,
drug was administered every 3 d. Clinical signs of arthritis
generally begin on day 10, and paw swelling was determined
every second day by water displacement plethysmometry. On
the day of sacriﬁce, a probe with a 24 g bending force was
applied to the lateral ankle of each hind paw for 4 s. Animals
were graded (0/1) on whether they vocalized. Radiographs
were obtained of the hind paws to assess bone changes by a
semiquantitative scoring system (demineralization (0 to 2þ),
ankle and mid-foot erosions (0 to 2þ), calcaneal erosion (0 to
1þ), and heterotopic bone formation (0 to 1þ) (maximum
possible score, 6). Paws were ﬁxed in formalin and decalciﬁed
for 2–3 d. Sections from parafﬁn-embedded tissue were
stained with hematoxylin and eosin. A synovial inﬂammation
score was determined using a semiquantitative scale that
measures synovial inﬂammation, cartilage integrity, bone
erosions, marrow inﬁltration, proteoglycan loss (in safranin
O-stained sections), and extra-articular inﬂammation. All
subjective assessments were made by an investigator blinded
to the drug treatment.
Immunostaining of Spinal Cords
Animals were deeply anesthetized with pentobarbital and
perfused ﬁrst with room-temperature 0.9% heparinized
saline containing phosphatase inhibitors then with 4%
chilled paraformaldehyde in 0.1 M phosphate buffer. Spinal
cords were removed, postﬁxed for 12 h, and cryoprotected in
30% sucrose. The ﬁxed tissue was mounted in Tissue-Tek
ornithine transcarbamylase embedding compound, snap
frozen, and stored at  80 8C. Sections (10 lm) were thaw-
mounted onto Superfrost Plus Slides and air-dried for 30
min. Serial sections and/or double staining of the same
section were used to determine colocalization of phosphory-
lated p38 (P-p38) (1:500, Cell Signaling Technology, Beverly,
Massachusetts, United States) with cell markers OX42 (1:100,
Biosource International, Camarillo, Texas, United States) for
microglia and NeuN (1:1,000, Chemicon, Temecula, Califor-
nia, United States) for neurons. Sections were incubated at 4
8C for 24 h and washed three times for 10 min each in PBS.
An ABC system (Vector Laboratories, Burlingame, California,
United States) with Cy3-, Cy2-, or FITC conjugated secondary
antibody were used for detection.
Western Blot Analysis
Animals were anesthetized with 4% isoﬂurane and sacri-
ﬁced, their spinal cords were removed by hydroextrusion, and
the lumbar enlargement homogenized in lysis buffer (50 mM
Tris, pH 7.4; 150 mM NaCl; 1 mM EDTA, pH 8; 0.5% Triton X-
100),proteaseinhibitorsandphosphataseinhibitors(Sigma,St.
Louis,Missouri,UnitedStates).Insolublematerialwasremoved
bycentrifugationat14,000gfor15minutesat48C.Theprotein
concentrations in the extracts were determined using the DC
protein assay reagent (Bio-Rad, Hercules, California, United
States). Lysates were fractionated on Tris-glycine-buffered
10% SDS-PAGE and transferred to nitrocellulose membrane
(Perkin-Elmer Life Sciences, Boston Massachusetts, United
States).ThemembraneswereblockedwithTris-bufferedsaline
and0.1%Tween20(TBS-T) containing 5% nonfatmilkfor 1h
at room temperature, followed by incubation with primary
antibody at 4 8C overnight. After washing with TBS-T, the
membrane was incubated with horseradish peroxidase-con-
jugated secondary antibody for 1 h at room temperature.
Immunoreactive protein was detected with chemilumines-
cenceandautoradiography(Perkin-Elmer),andanalyzedusing
National Institutes of Health (NIH) Image software (version
1.61, NIH, Bethesda, Maryland, United States).
Q-PCR
Ankle joints were excised and trimmed of skin. The tissue
was then pulverized and RNA extracted using RNA-STAT-60
and standard techniques. The RNA was reversed transcribed
into cDNA using random hexamer primers. TaqMan PCR
ampliﬁcation reactions were carried out in reaction volumes
of 25 ll in MicroAmp Optical Plates and MicroAmp Optical
Caps using the TaqMan Universal Master Mix with a Perkin
Elmer 5700 thermal cycler. Each sample was analyzed in
triplicate using 50 ng of cDNA in the reaction. Thermal
cycling was initiated with an incubation at 50 8C for 2 min,
followed by 95 8C for 10 min to activate the AmpliTaq
polymerase, then 40 cycles of 95 8C for 15 s and 60 8C for 1
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The standard curve method was used for quantiﬁcation as
previously described [6].
CSF Collection and TNFa Assay
Halothane-anesthetized rats were placed in the prone
position and the spinous processes at L1/L2 were identiﬁed as
a tactile landmark. A midline skin incision, approximately 3
cm in length, was made caudally from the landmark to expose
the interspinous space at L4/L5. The L4/L5 interspinous
ligament and L5 spinous process were carefully removed.
While elevating the L4 spinous process with forceps to widen
the L4/L5 interlaminar space, the tip of a pulled capillary
tube was obliquely introduced into the IT space. The jugular
veins were compressed to increase the IT pressure and 40–50
ll of clear CSF was collected by capillary action. The CSF was
transferred to microcentrifuge tubes, immediately frozen on
dry ice and stored at 70 8C until assayed for TNFa by ELISA
according to the manufacturer’s instructions (R & D Systems,
Minneapolis, Minnesota, United States).
T Cell Proliferation Assay
Catheterized rats were immunized with CFA on day 0.
Beginning on day 8, rats were treated with IT vehicle or 8 lg
of SB203580. The animals were then sacriﬁced on day 14.
Draining lymph node cells were isolated, washed with DMEM
containing 2% FCS, and cultured in triplicate in 200 ll, U-
bottom microtiter wells at 4 3 10
5 cells per well with or
without antigen in DMEM supplemented with 10% fetal
bovine serum, penicillin, and streptomycin. L-glutamine and
5310
 5 M b-mercaptoethanol. Lymph node cells were tested
for proliferation in response to ovalbumin at 1 lg/ml, HSP65
at 1 lg/ml, HSP65 180–188 peptide at 10 lg/ml, or Con A (2
lg/ml). Cells were incubated for 96 h at 37 8C in a humidiﬁed
atmosphere of 5% CO2 [7]. Cultures were pulsed for the ﬁnal
16 h with [
3H]thymidine (Amersham; 1 lCi/well, speciﬁc
activity 1 Ci/mmol), and thymidine uptake was measured
using a liquid scintillation beta counter. Results are expressed
as the mean cpm of triplicate cultures of stimulated cells
minus medium control.
Statistical Analyses
Means and standard errors of the mean are presented for
all values. Data were analyzed by ANOVA followed by
Dunnett’s post-hoc test, the Student’s t-test, or the Chi square
test as appropriate.
Results
Phosphorylation of p38 MAP Kinase in the Spinal Cord in
Adjuvant Arthritis
Initial experiments were performed to determine whether
spinal p38 is phosphorylated in rats during the course of
adjuvant arthritis (Figure 1). Rats were immunized with CFA
on day 0 and sacriﬁced at various time points. Spinal cords
were harvested and Western blot analysis was performed on
the lumbar enlargements. As shown in Figure 1A, P-p38 levels
increased in individual rats between days 8 and 17 after
immunization. For comparison, COX2 expression was de-
tected on day 5 and was elevated throughout the course of the
model. To determine the location of P-p38-expressing cells,
immunized rats were perfused on day 10, and tissue sections
from the L4/L5 spinal cords were immunostained with anti-P-
p38 antibody. Whereas dorsal horns of control rats contained
only a few scattered P-p38-positive cells, numerous cells
stained positively for P-p38 in the CFA-immunized rats
(Figure 1B). These cells were present throughout the dorsal
horn parenchyma, with especially dense staining in super-
ﬁcial laminae (especially lamina II). To determine which cell
types express P-p38 in arthritic animals, double staining was
performed using anti-P-p38 and antibodies speciﬁc for
activated microglial cells (OX-42) or neurons (NeuN). Double
staining with OX-42 showed (in merged images; see Figure 1E
for a representative ﬁeld and Figure 1I for an enlargement)
that the majority of P-p38 staining was located in microglial
cells. Double staining studies with NeuN also showed a limited
number of neurons expressing P-p38 that were conﬁned to
lamina II (see Figure 1F–1H and 1J).
IT MAP Kinase Inhibitor Suppresses Adjuvant Arthritis
We then examined the effect of daily bolus injection of IT
SB203580 (8 lg) on the clinical manifestations of adjuvant
arthritis. As shown in Figure 2, paw swelling was markedly
decreased in rats treated daily with IT SB203580 compared to
either IT saline or the same dose of the inhibitor adminis-
tered subcutaneously (SC) to catheterized rats. Rats with IT
drug treatment did not respond to ankle pressure with
vocalization (pain response), in contrast to rats with either IT
saline or systemic drug administration (Table 1).
IT MAP Kinase Inhibitor Suppresses Joint Destruction and
Synovial Cytokine Gene Expression
Radiographic evidence of joint damage was also deter-
mined in the adjuvant arthritis model (Figure 3). IT
treatment with the p38 inhibitor markedly decreased radio-
graphic scores of joint damage, including bone erosions,
cartilage loss, and demineralization, while systemic treatment
with the same dose had no effect (Figure 3A). Representative
radiographic images demonstrate the protective effect of IT
SB 203580 (Figure 3B). The ankle histology in adjuvant
arthritis also showed a trend toward less synovial inﬂamma-
tion, bone erosion, and cartilage loss in rats that received IT
SB203580 (Figure 3C). The improvement in joint destruction
after treatment with IT SB203580 suggests that the mediators
and effector molecules in the joint might be affected by
spinal p38 blockade. To evaluate this question, synovial gene
expression of proinﬂammatory cytokines was determined
using quantitative real-time PCR. Figure 3C shows that the IT
p38 inhibitor signiﬁcantly decreased synovial IL-1 (p ¼ 0.025)
and IL-6 (p ¼ 0.006) mRNA in arthritis and there was a trend
toward a decrease in TNFa mRNA (p ¼ 0.089). Furthermore,
expression of a key gene involved with extracellular matrix
degradation (MMP3) was also decreased (p ¼ 0.001; Figure
3D).
IT SB203580 Does not Inhibit Peripheral T Cell
Proliferation
In contrast to the effects on synovial cytokine expression,
treatment of CFA-immunized rats with IT SB20580 had no
effect on T cell proliferation. Table 2 shows the results of an
experiment in which arthritic rats were treated from day 8
through day 14 with IT SB20580. Draining lymph node cells
were harvested and cultured in the presence of epitopes
implicated in adjuvant arthritis (HSP65 or the peptide HSP65
180–188, derived from HSP65) [8], ovalbumin, or the non-
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levels of proliferation in treated and control rats. No
proliferation was observed using the control protein (oval-
bumin), and no differences were observed between the
groups stimulated with Con A.
Mechanism of p38 Activation: Role of TNFa
One possible mechanism of IT p38 blockade is through
spinal TNFa, which is induced in the spinal cords of rats with
adjuvant arthritis [9]. TNFa could potentially function
upstream of p38 by activating kinases that phosphorylate
p38, or it could be a downstream effect of p38 activation. If
local TNFa is responsible for p38 activation and the
subsequent proinﬂammatory effects, then spinal TNFa block-
ade in the CNS should theoretically suppress adjuvant
arthritis and P-p38 levels. To test this hypothesis, we treated
Figure 1. Phosphorylation of p38 MAP Kinase in the Spinal Cord
(A) Western blot analysis of p38, P-p38, and COX2 in the spinal cord of
rats with adjuvant arthritis. Rats were sacrificed from day (D) 0 through
day 17. Note faint P-p38 staining on days 8 to day 17. GAPDH normalized
expression ¼ 0.22 6 0.02 for prearthritis (days 0–5) and 0.32 6 0.3
postarthritis (days 8–17; p ¼ 0.0255).
(B) Low-power view showing P-p38 expression in adjuvant immunized
rats, especially in lamina II (CST, corticospinal tract).
(C–E) High power view of P-p38 (C), OX-42 (D), and merged view (E)
demonstrating expression of P-p38 in microglia of adjuvant immunized
rats.
(F–H) High-power view of P-p38 (F), NeuN (G), and merged view (H)
demonstrating scattered neurons expressing P-p38 in adjuvant immu-
nized rats.
(I) and (J) show higher power view of (E) and (H), respectively.
Arrow indicates positively staining cells in all photomicrographs.
DOI: 10.1371/journal.pmed.0030338.g001
Figure 2. Effect of IT p38 Inhibitor on Paw Swelling in Adjuvant Arthritis
Rats were immunized with CFA on day 0 and treated daily with IT p38
inhibitors (SB203580 at 8 lg/d), SC p38 inhibitor (SB203580 at 8 lg/d), or
IT saline beginning on days 8–20. Paw swelling was measured by water
displacement plethysmometry. The IT p38 inhibitor significantly
decreased paw swelling (*p ¼ 0.001 by ANOVA and Dunnett’s post-
ANOVA test; n¼5–6/group). This graph presents data from one of three
separate experiments with similar results.
DOI: 10.1371/journal.pmed.0030338.g002
Table 1. Behavioral Pain Effect of IT p38 Inhibitor in Adjuvant
Arthritis
Treatment Positive Vocalization
a
IT Saline 4/5
IT SB203580 0/6
b
SC SB203580 4/6
No arthritis 0/5
a24 g bending force was applied to the lateral ankle of each hind paw for 4 s on day 20
after immunization. The number of animals that vocalized compared with the total
number is shown.
bp ¼ 0.01 compared with IT saline (Chi-square test).
DOI: 10.1371/journal.pmed.0030338.t001
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inhibitor etanercept IT every 3 d beginning on day 1. As
shown in Figure 4A and 4B, etanercept signiﬁcantly
decreased paw swelling and joint destruction. Similar results
were obtained in a second experiment when treatment was
initiated on day 8 instead (unpublished data). Systemic
treatment with the same doses of etanercept had minimal
effect on paw swelling by day 20 (see Figure 4C). To
determine if spinal TNFa is responsible for p38 activation,
CFA-immunized rats administered either IT vehicle or
etanercept on days 7 and 10 were sacriﬁced on day 11;
immunostaining and Western blot analysis on these animals
showed that etanercept decreased P-p38 expression, suggest-
ing that TNFa acts upstream of p38 activation in this model
(Figure 4D and 4E).
To determine if p38 also regulates TNFa expression in the
spinal cord, a second series of experiments were performed
to determine if IT SB203580 decreased TNFa levels in the
CSF of catheterized rats with adjuvant arthritis. Rats were
immunized on day 0 and treated with vehicle or IT SB203580
from days 8 to 14. CSF was collected and assayed for TNFa by
ELISA. TNFa expression did decrease in response to the p38
inhibitor: In the vehicle-treated group, TNFa was 23.3 6 11.0
pg/ml, whereas in the SB20358-treated group it was 7.6 6 2.6
pg/ml (p¼0.038, n¼3 for saline and n¼4 for SB203580; TNFa
, 0.5 pg/ml in normal rats).
Table 2. Effect of IT p38 Inhibitor on T Cell Proliferation in
Adjuvant Arthritis
Treatment Ovalbumin HSP65 180–188 HSP65 Con A
Saline ,200 3,770 6 441 9,120 6 750 40,900 6 3,850
IT SB203580 ,200 2,170 6 379 7,510 6 1,067 43,200 6 4,958
Draining lymph node cells from CFA-immunized mice were harvested on day 14 and
cultured in the presence of HSP peptides, ovalbumin, or Con A. Proliferation was
determined by [
3H]thymidine incorporation and is presented here as the mean cpm 6
standard error of the mean of the test sample minus medium control. n¼5 for saline and
n¼6 for IT SB203580 from days 8–14. p¼0.267 for IT saline versus IT SB203580 for each
antigen.
DOI: 10.1371/journal.pmed.0030338.t002
Figure 3. Effect of IT p38 Inhibitor on Joint Damage and Gene Expression
in Adjuvant Arthritis
Rats were immunized with CFA on day 0 and treated daily with IT
SB203580 (8 lg) or IT saline beginning on days 8–20.
(A) Radiographs of the hind paws were evaluated using a scoring system
that demonstrated decreased damage in the SB203580-treated group
compared with control rats. *p ¼ 0.036 for IT SB203580 (n ¼ 6/group).
Similar results were observed in a separate experiment with treatment
beginning on day 8 (n ¼ 5–6/group).
(B) Representative radiographs illustrate decreased joint destruction in
the treated group.
(C) Representative hematoxylin and eosin-stained sections demonstrate
decreased erosions, cartilage damage, and synovial inflammation in the
IT SB203580-treated group.
(D) Quantitative real-time PCR was performed on the hind paws as
described in Methods. Normal rat joints are also shown as a control. IT
SB203580 significantly decreased IL-1 (*p¼0.025), IL-6 (**p¼0.006), and
MMP3 (þp ¼ 0.001) gene expression (n ¼ 5–6/group); TNFa gene
expression was modestly reduced, but did not reach statistical
significance ( ^ p ¼ 0.089).
DOI: 10.1371/journal.pmed.0030338.g003
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Neural processing in the CNS can inﬂuence somatic host
responses in the peripheral tissues, but the mechanisms
remain poorly deﬁned. The current study identiﬁes an
intracellular mechanism, to our knowledge not yet described,
that involves spinal p38 MAP kinase as a link between the
periphery and the CNS. Our results suggest that spinal
Figure 4. Effect of IT Etanercept on Adjuvant Arthritis
Rats were immunized with CFA on day 0 and treated with IT etanercept (100 or 300 lg q.o.d.) beginning on day 1.
(A) IT etanercept (Etan) significantly decreased paw swelling (*p ¼ 0.001 for IT saline compared with either IT etanercept group) (n ¼ 6/group).
(B) IT etanercept significantly decreased joint damage (by radiographic score; *p¼0.026 for IT saline compared with either IT etanercept group) (n¼6/
group).
(C) Similar doses of etanercept given systemically (SC) beginning on day 1 had minimal effect on paw swelling (p ¼0.398 for IT saline compared with
either etanercept group) (n ¼ 6/group).
(D and E) IT etanercept decreased spinal P-p38 staining in adjuvant arthritis. Rats were immunized on day 0 and injected IT with 300 lg of etanercept or
vehicle on days 7 and 10. They were sacrificed on day 11 and P-p38 was determined by Western blot (D) and immunofluorescence (E). Western blot data
were normalized to GAPDH and demonstrated significantly lower levels of P-p38 after IT etanercept treatment (n¼6 for etanercept, 4 for saline, and 2
for naı ¨ve). *p ¼ 0.023 compared with IT saline.
DOI: 10.1371/journal.pmed.0030338.g004
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mation, arthritis, proinﬂammatory gene expression, and joint
destruction.
The potential contribution of the spinal cord to peripheral
inﬂammation has been explor e di na c u t ea n dc h r o n i c
inﬂammation models, especially with agents that modulate
glutamate and adenosine receptors [10]. Spinal administra-
tion of an adenosine A1 receptor agonist suppresses skin
inﬂammation [2]. This action is independent of the sympa-
thetic nerves and of dopaminergic activity, and it requires
afferent input and/or dorsal root reﬂexes for the anti-
inﬂammatory activity [11]. Other studies deﬁning the
inﬂuence of the CNS on peripheral inﬂammation have
focused on vascular leakage rather than inﬂammatory cell
recruitment. For instance, peripheral sympathectomy de-
creases paw edema in adjuvant arthritis, although it has no
effect on neutrophil inﬁltration in carrageenan-injected skin
[12,13]. Release of substance P at the site of inﬂammation
probably accounts for primary effects on vascular integrity
rather than neutrophil trafﬁcking [14–16]. Studies in intra-
articular carrageenan-induced inﬂammation models demon-
strate that spinal non-N-methyl-D-aspartate (NMDA) gluta-
mate receptor subtypes mediate the edema [1]. In contrast,
neurogenic edema resulting from intradermal capsaicin
injection is blocked by both non-NMDA and NMDA
antagonists [17–19]. These contrasting results point to a high
level of receptor activation speciﬁcity with variations in their
peripheral effects depending on the type of inﬂamed tissue.
MAP Kinase Activation in the Spinal Cord
While spinal glutamate receptor activation has been
extensively evaluated in inﬂammation models, the role of
intracellular signaling pathways such as those mediated by
spinal MAP kinases is not known. MAP kinases in the
peripheral tissues play a critical role in innate immunity
and host defense by regulation of cytokines such as IL-1, IL-6,
and TNFa and of enzymes involved in tissue remodeling, such
as MMPs. Surprisingly, the same pathways are activated in
spinal cord microglia and to a lesser extent in neurons when
peripheral nerves are injured [20]. For instance, P-p38
increases in spinal cord within several hours of spinal nerve
ligation (a standard model of neuropathic pain) [21]. MAP
kinase blockade by spinal administration of a p38 inhibitor
substantially reduces sciatic nerve ligation-induced mechan-
ical allodynia. After unilateral chronic constriction injury to
the mid-sciatic nerve or axotomy, spinal P-p38 is elevated for
up to two weeks [22]. Spinal extracellular signal-regulated
kinase (ERK) and c-Jun N-terminal kinase phosphorylation
also peak in dorsal horn astrocytes three weeks after partial
sciatic nerve ligation [23].
Data on activation of MAP kinases in the CNS due to
inﬂammation are less well established. One study showed that
carrageenan injection into rat foot pads induces a 5-fold
increase in spinal ERK phosphorylation [24]. A similar
increase in ERK activation occurs in an inﬂammatory pain
model induced by injection of CFA into a rat paw [25].
Immunohistochemical studies show that both neurons and
glia in the spinal cord contain the activated kinase. ERK
activation after formalin injection appears to require
metabotropic glutamate receptors rather than NMDA recep-
tors [26]. Recent studies suggest that p38 is also activated in
spinal cord by injection of carrageenan or formalin into the
footpad [4,22], and inhibition of p38 reduces pain behavior
associated with the peripheral inﬂammation. However, a
study examining the spinal sequelae of a monoarthritis
induced by intraplantar CFA reported no phosphorylation
of p38 [27]. Another study reported that spinal administra-
tion of NMDA increased P-p38 in superﬁcial dorsal horn,
predominantly in microglial neurons, but also in a signiﬁcant
number of lamina II neurons [28]—much the same pattern
that we observed in the current study with synovial
inﬂammation.
Spinal p38 Blockade Suppresses Arthritis
Based on the studies demonstrating that nerve injury is
associated with MAP kinase activation in the spinal cord and
that p38 blockade has antihyperalgesic activity in animal
models, we explored the possibility of a corresponding effect
on peripheral inﬂammation. We examined the activation
state of p38 in the spinal cord during the evolution of chronic
arthritis. Initial Western blot studies showed that p38 is
phosphorylated in the spinal cord during the evolution of the
adjuvant model. The kinase is activated in speciﬁc regions of
the spinal cord dorsal horn within one week. Both neurons
and microglial cells in the spinal cord contain P-p38,
although double staining studies suggest that the latter is
the primary location. A therapeutic intervention with IT
SB203580, a commonly used p38 inhibitor, markedly
decreased paw swelling and hyperalgesia. The amount
required was a small fraction of the dose required if the
same compound was administered systemically, and the same
low dose given SC had no effect in arthritic rats. More
striking, inhibition of p38 in the CNS also decreased synovial
inﬂammation and radiographic evidence of bone and
cartilage destruction. Expression of genes for proinﬂamma-
tory cytokines and matrix metalloproteinases was also
reduced by inhibition of p38 in the spinal cord.
Systemic p38 blockade has been extensively studied in
inﬂammation and clearly demonstrates beneﬁt in several
models of arthritis [29–31]. The biological effects are similar
to those observed in our studies evaluating IT administration
of SB203580. Not only is synovial inﬂammation decreased,
but joint damage is markedly attenuated by systemic p38
inhibition. One common observation is that relatively high
doses of p38 inhibitors are often required when delivered by
oral or parenteral routes, and the effective dose in vivo is
often several hundred-fold higher than the amount required
via IT therapy. These observations raise the intriguing
possibility that the CNS might be responsible for a
component of the anti-inﬂammatory effects seen with
systemic administration of p38 inhibitors, and that inad-
equate CNS penetration contributes for this discrepancy.
Spinal TNFa Blockade in Arthritis
The mechanism of central anti-inﬂammatory effects re-
quires the expression of spinal or dorsal root ganglion TNFa.
Noxious stimuli in the periphery, including adjuvant arthritis,
enhance spinal TNFa release [9], and etanercept, a TNFa
antagonist,inhibits allodynia and p38 activation in spinal cord
when administered IT before spinal nerve ligation [32].
However, TNFa could either be the result of p38 phosphor-
ylation or the cause of p38 activation in neurons and
microglia in inﬂammation. Previous studies have documented
that spinal TNFa expression is increased in the adjuvant
PLoS Medicine | www.plosmedicine.org September 2006 | Volume 3 | Issue 9 | e338 1622
Spinal p38 and MAP Kinasearthritis model [9]. To evaluate the role of TNFa in the
mechanism of IT SB203580 action, we administered etaner-
cept IT in this model. Our data show that spinal TNF blockade
mimics the anti-inﬂammatory and bone-protective effects of
the p38 inhibitor. Furthermore, etanercept blocked spinal
p38 phosphorylation, placing the cytokine upstream of the
MAPkinase in the neural regulation of inﬂammation. The role
of TNFa is probably more complex, because p38 can regulate
production of this cytokine. Our data suggest that p38
inhibition also suppresses TNFa levels in the CSF of
catheterized rats with adjuvant arthritis. The most likely
explanation is that TNFa expression in the spinal cord both
induces and is induced by p38 activation.
The mechanism by which the CNS modulates peripheral
inﬂammation is not yet known. We have explored whether
general or antigen-speciﬁc suppression of T cell function
could account for our observations. T cell responses to
epitopes implicated in the pathogenesis of adjuvant arthritis
were not inhibited by treatment with an IT p38 inhibitor [8].
In other systems, the anti-inﬂammatory effect is independent
of peripheral cytokines and is mediated by the release of
adenosine in the peripheral tissue [2]. An efferent neural
component rather than a circulating factor is responsible,
because denervation inhibits the anti-inﬂammatory effects
[11]. For instance, Tracey and colleagues have shown that
parasympathetic outﬂow from the vagal nerve can suppress
peripheral macrophage function and systemic inﬂammation
via central muscarinic receptors [33]. Intraventricular treat-
ment with CNI-1493, which inhibits p38, c-Jun N-terminal
kinase, and perhaps other kinases, suppresses TNFa produc-
tion and peripheral inﬂammatory responses [34]. The
potential role of the parasympathetic nervous system in the
adjuvant arthritis model is currently being investigated.
Conclusions and Future Directions
Any study evaluating pain and inﬂammation in preclinical
models has limitations, and this one is no exception. While
adjuvant arthritis has many similarities to rheumatoid
arthritis, no animal precisely replicates the human condition.
There is also no guarantee that the pathways implicated in
rodents have exact parallels to humans; this information can
only be derived from clinical trials. Despite these issues, data
implicating the CNS in peripheral inﬂammation could have
relevance to the role of stress on immune responses,
susceptibility to autoimmunity, and perhaps even placebo
effects in patients.
We propose that inﬂammation in peripheral tissues is
sensed by the CNS, most likely through somatic afferent
pathways. This results in local TNFa production followed by
p38 activation. The MAP kinase intracellular signaling path-
way can subsequently relay information to the periphery,
which is essential for full expression of somatic host responses.
It is possible that this efferent ﬂow occurs via activation of
dorsal root reﬂexes in the somatic nerves, as has been shown
for the vascular models; we are currently investigating the
precise mechanism. Because glutamate receptor stimulation
can increase spinal p38 phosphorylation [28], it is also possible
that p38 links the previously described anti-inﬂammatory
glutamate receptor mechanisms to the present study.
In addition to providing insights on the interactions
between the CNS and host defense, this novel MAP kinase-
dependent pathway could inﬂuence the design of p38
inhibitors. Rather than focus exclusively on target organs for
drug development, such as the synovium, or assiduously
prevent entry into the CNS, it might be more appropriate to
develop compounds that can penetrate the blood-brain
barrier. This approach could offer the dual advantage of
maximizinganti-inﬂammatoryactionandenhancinganalgesic
effects.
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Editors’ Summary
Background. Rheumatoid arthritis is a disease marked by chronic
inflammation, leading to joint pain and destruction. Pain and inflamma-
tion in the joints as well as other locations in the body (i.e., the
‘‘periphery’’) are constantly monitored by the central nervous system
(i.e., the brain and spinal cord). Scientists have long suspected that the
central nervous system (CNS) can regulate inflammation and immune
responses, but little is known about how the CNS does this. One
potential player is a protein called p38 that is involved in a number of
cellular processes critical to the development of rheumatoid arthritis.
Several substances that block the action of p38 are effective in animal
models of arthritis and are currently being tested in clinical trials in
patients with rheumatoid arthritis. Originally, p38 was considered as a
drug target that should mainly be blocked in the joints. But recent work
has shown that pain in the periphery can lead to activation of p38 in the
spinal cord, and that blocking p38 in the spinal cord might reduce
peripheral pain.
Why Was This Study Done? Based on the observation that p38 is
activated in the CNS in response to peripheral pain, the researchers who
did this study wondered whether it might be involved in the interaction
between inflammation in the joints and the CNS.
What Did the Researchers Do and Find? They induced inflammation in
the joints of rats and then looked for responses in the spinal cord. They
found that p38 was indeed activated in the spinal cord of these rats. This
activation depended on another protein, called TNFa, which is another
major regulator of inflammation. The scientists then blocked either p38
or the TNFa with drugs directly delivered to the spinal cord of the
arthritic rats, they could substantially reduce inflammation, arthritis, and
destruction of the joints, compared with rats that had undergone the
same treatment but received no active drug. Treatment of arthritic rats
with the same amount of drugs given directly under the skin (this is
called ‘‘systemic treatment’’) did not have any effect on the joints.
What Do These Findings Mean? Blocking p38 and TNFa by giving
drugs systemically is known to have beneficial effects in animal models
and human patients with rheumatoid arthritis. However, the drugs
tested in patients to date also have side effects. Given that much lower
doses were needed to achieve beneficial effects in the rats when the
drugs were administered directly into the spinal cord, it is possible that
spinal cord administration might reduce the side effects (and possibly
the costs) of the drugs without compromising the benefits to the
patients. If future studies confirm that the action of these drugs on the
CNS is essential to achieve a response even when administered as a
systemic treatment, designing drugs that get into the CNS easier might
improve the effectiveness and/or make it possible to use lower doses
systemically.
Additional Information. Please access these Web sites via the online
version of this summary at http://dx.doi.org/10.1371/journal.pmed.
0030338.
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